Eisai to Acquire Global Rights to Four Oncology-Related Products from Ligand Pharmaceuticals (LGND)
More News related to LGND
- Ligand Pharma (LGND) Reports Data on SARM
- Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting
- Ligand Pharma (LGND) Receives $2M in Milestone Payments from N.V. Organon
- Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc.
- Morning Movers 11/06: ACLS, CVM, ZIOP, LPSN, CABL, ZGEN Higher; NHWK, GOK, CROX, CVI, RAIL, CSTR Lower
More News related to Mergers and Acquisitions
- Metalline Mining (MMG) and Dome Ventures Agree to Merger Deal
- Pepsi (PEP) Company Completes Acquisition of Conway-Myrtle Beach Bottler
- Hershey (HSY), Nestle said to have been in contact about Cadbury (CBY)
- Kraft Singles Itself Out as Buyer for Cadbury
- Brookfield Positions To Bid for General Growth Properties (GGWPQ)
Eisai has announced that it signed a product acquisition agreement with Ligand Pharmaceuticals (Nasdaq: LGND) for exclusive global rights for their four oncology-related products, ONTAK, Targretin capsules, Targretin gel 1% and Panretin gel 0.1%.
The transaction is subject to governmental approvals and is expected to close after certain preparation period. Eisai will pay U.S. $205 million for the acquisition, and offer Ligand personnel employment by Eisai Inc
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
